TwoStep Therapeutics reposted this
My answer to the platform vs asset debate in techbio: Great platforms build great assets. But, you have to be strategic. It's about balance. You can advance a lead asset, while leveraging your platform (services, targets, other assets) to gain revenue + grow your platform. If you do it right, you create a cycle of growth. Our advice on striking this balance: https://lnkd.in/gVRxU7SU Quick examples below: Most companies fall somewhere on a continuum between monetizing the platform itself vs using assets to fuel platform development. Example: Twist Bioscience. They monetized a DNA synthesis platform and became a huge company. They pivoted toward assets later. But most bioplatforms aren't like that. Most need to pursue assets earlier to fuel development and show traction. Example: Mammoth Biosciences owns key IP in small CRISPR systems and has monetized various aspects of that IP through pharma deals. These partnerships boosted their credibility and funded future R&D. Now, they have strong pharma ties and millions in non-dilutive funding for internal development. My most recent essay tackles striking this balance, and what you need to show by Series A to be on the right track.